Chantal Marx of FNB Wealth & Investments on what the smart money is doing
11 April 2024 - 05:00
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Chantal Marx, head of investment research and content: FNB Wealth & Investments
Buy: Bidvest (long term)
Bidvest’s share price has not fully recovered after a soft trading update released in November. Management flagged a slowdown prior to the release, but the depth of pressure on volumes and margins in the consumer-facing businesses was more severe than anticipated. The interim results released in March, however, showed that despite this pressure the overall performance was relatively resilient — testament to the company’s diversified business model and management’s cost-containment efforts. The outlook statement was relatively positive, with management remaining confident in the group’s growth prospects. The group also has a pipeline of reasonably sized acquisitions that are being considered, which could complement its organic growth profile. We would expect a recovery in most of the strained businesses as economic conditions improve (expected from mid-2024).
The share price is trading about 15% below its November highs (on a total return basis), and more than one standard deviation below its forward p:e and EV/ebitda averages over time. We think current levels present attractive upside for long-term investors. Technically, the stock is trading near major support, which will limit downside potential barring any significant negative surprise on the fundamentals. Still, we recommend a stop loss at R229 as this level could trigger a technical sell-off.
Sell: MultiChoice (profit take)
We still like MultiChoice from a long-term perspective, but the Canal+ offer of R125 may limit near-term upside potential. Because of heavy near-term investment in Showmax, we don’t think investors have much bargaining strength in pushing for a higher offer price and there is also substantial downside risk should the deal not go through. The regulatory hurdles attached to this deal may also result in it taking quite some time to be concluded and there will be an opportunity cost attached to staying invested in the stock while it trades close to the deal price over this time.
We will reconsider a long position in the combined entity should it ultimately list on the JSE.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
BROKERS’ NOTES: Buy Bidvest, sell MultiChoice
Chantal Marx of FNB Wealth & Investments on what the smart money is doing
Chantal Marx, head of investment research and content: FNB Wealth & Investments
Buy: Bidvest (long term)
Bidvest’s share price has not fully recovered after a soft trading update released in November. Management flagged a slowdown prior to the release, but the depth of pressure on volumes and margins in the consumer-facing businesses was more severe than anticipated. The interim results released in March, however, showed that despite this pressure the overall performance was relatively resilient — testament to the company’s diversified business model and management’s cost-containment efforts. The outlook statement was relatively positive, with management remaining confident in the group’s growth prospects. The group also has a pipeline of reasonably sized acquisitions that are being considered, which could complement its organic growth profile. We would expect a recovery in most of the strained businesses as economic conditions improve (expected from mid-2024).
The share price is trading about 15% below its November highs (on a total return basis), and more than one standard deviation below its forward p:e and EV/ebitda averages over time. We think current levels present attractive upside for long-term investors. Technically, the stock is trading near major support, which will limit downside potential barring any significant negative surprise on the fundamentals. Still, we recommend a stop loss at R229 as this level could trigger a technical sell-off.
Sell: MultiChoice (profit take)
We still like MultiChoice from a long-term perspective, but the Canal+ offer of R125 may limit near-term upside potential. Because of heavy near-term investment in Showmax, we don’t think investors have much bargaining strength in pushing for a higher offer price and there is also substantial downside risk should the deal not go through. The regulatory hurdles attached to this deal may also result in it taking quite some time to be concluded and there will be an opportunity cost attached to staying invested in the stock while it trades close to the deal price over this time.
We will reconsider a long position in the combined entity should it ultimately list on the JSE.
ALSO READ:
BROKERS’ NOTES: Buy Super Group, sell Impala Platinum
BROKERS’ NOTES: Buy Prosus, sell Clicks
BROKERS’ NOTES: Buy Oracle, sell Hyprop
Companies in this Story
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.